Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation Scott D. NelsonDaniel MaloneJoanne Lafleur Practical Application 06 May 2015 Pages: 887 - 892
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective Nigel FleemanAdrian BagustLindsay Banks Review Article 24 April 2015 Pages: 893 - 904
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review Bonny ParkinsonCatherine SermetAdam G. Elshaug Review Article 06 June 2015 Pages: 905 - 924
The Economic and Humanistic Burden of Severe Sepsis Bogdan TiruErnest K. DiNinoWilliam T. McGee Review Article 03 May 2015 Pages: 925 - 937
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review Yoko V. LaurenceUlla K. GriffithsAnna Vassall Systematic Review Open access 05 May 2015 Pages: 939 - 955
Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia Sabina SangheraEmma FrewTracy Elizabeth Roberts Original Research Article Open access 25 April 2015 Pages: 957 - 965
A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark Anne Sig VestergaardLars Holger Ehlers Original Research Article 06 May 2015 Pages: 967 - 979
Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy” Afschin Gandjour Letter to the Editor 30 July 2015 Pages: 981 - 982
The Authors’ Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy” Janneke P. C. GruttersMarjolein B. A. van AsseltManuela A. Joore Letter to the Editor 28 August 2015 Pages: 983 - 983
